Neurocrine announces completion of phase II clinical study of VMAT2 inhibitor INGREZZATM
Neurocrine announced the top-line results from the Company's Phase II T-Forward study of INGREZZA™ (valbenazine), a highly-selective small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in adults with Tourette syndrome. The pre-specified primary endpoint was not met. January 17, 2017